Is our clinical practice of antipsychotic relapse prevention in schizophrenia really evidence-based?;Ist unsere praxis der medikamentösen rückfallprophylaxe bei schizophrenen psychosen wirklich evidenzbasiert?

Neuropsychiatrie

Volumn 24, Issue 1, 2010, Pages 14-26

  Schanda, Hans ^a,b   Stompe, Thomas ^a,b  

^a Justizanstalt Göllersdorf ^*  (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Antipsychotics; Depot medication; Medication adherence; Relapse prevention; Schizophrenia

Indexed keywords

LONG ACTING DRUG; NEUROLEPTIC AGENT;

CLINICAL ASSESSMENT; CLINICAL PRACTICE; DRUG DOSAGE FORM COMPARISON; EVIDENCE BASED PRACTICE; HUMAN; PATIENT AUTONOMY; PATIENT COMPLIANCE; RELAPSE; REVIEW; SCHIZOPHRENIA; DELAYED RELEASE FORMULATION; EVIDENCE BASED MEDICINE; INTRAMUSCULAR DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; PSYCHOLOGY; RECURRENT DISEASE;

ADMINISTRATION, ORAL; ANTIPSYCHOTIC AGENTS; DELAYED-ACTION PREPARATIONS; EVIDENCE-BASED MEDICINE; HUMANS; INJECTIONS, INTRAMUSCULAR; MEDICATION ADHERENCE; PHYSICIAN'S PRACTICE PATTERNS; RECURRENCE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 77957004326     PISSN: 09486259     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (109)

1. Academic Highlights: Guidelines for the use of long-acting injectable atypical antipsychotics. J Clin Psychiatry 65, 120-129 (2004).
2. Acosta F.J., Bosch E., Sarmiento G., Juanes N., Caballero-Hidalgo A., Mayans T.: Evaluation of noncompliance in schizophrenia using electronic monitoring (MEMS® ) and its relationship to sociodemographic, clinical and psychopathological variables. Schizophr Res 107, 213-217 (2009).
3. Adams C.E., Fenton M.K.P., Quraishi S., David A.S.: Systematic meta-review of depot antipsychotic drugs for people with schizophrenia. Br J Psychiatry 179, 290-299 (2001).
4. Allebeck P.: Schizophrenia: a life-shortening disease. Schizophr Bull 15, 81-89 (1989).
5. Almond St., Knapp M., Francois C., Toumi M., Brugha T.: Relapse in schizophrenia: costs, clinical outcomes and quality of life. Br J Psychiatry 184, 346-351 (2004).
6. Angermeyer M.C., Matschinger H.: Causal beliefs and attitudes to people with schizophrenia: trend analysis based on data from two population surveys in Germany. Br J Psychiatry 186, 331-334 (2005).
7. Ascher-Svanum H., Faries D.E., Zhu B., Ernst F.R., Swartz M.S., Swanson J.W.: Medication adherence and long-term outcome in the treatment of schizophrenia in usual care. J Clin Psychiatry 67, 453-460 (2006).
8. Baranyi A., Yazdani R., Haas-Krammer A., Stepan A., Kapfhammer H.P., Rothenhäusler H.B.: Atypische Neuroleptika und metabolisches Syndrom. Wien Med Wochenschr 157, 255-270 (2007).
9. Brekke J.S., Prindle C., Woo Bae S., Long J.D.: Risk for individuals with schizophrenia who are living in the community. Psychiatr Serv 52, 1358-1366 (2001).
10. Brown St.: Excess mortality of schizophrenia. A meta-analysis. Br J Psychiatry 171, 502-508 (1997).
11. Byerly M., Fisher R., Whatley K., Holland R., Varghese F., Carmody T., Magouirk B., Rush A.J.: A comparison of electronic monitoring vs. clinician rating of antipsychotic adherence in outpatients with schizophrenia. Psychiatry Res 133, 129-133 (2005).
12. Byerly M.J., Nakonezny P.A., Lescouflair E.: Antipsychotic medication adherence in schizophrenia. Psychiatr Clin North Am 30, 437-452 (2007).
13. Chue P., Emsley R.: Long-acting formulations of atypical antipsychotics: time to reconsider when to introduce depot antipsychotics. CNS Drugs 21, 441-448 (2007).
14. Cramer J.A., Rosenheck R.: Compliance with medication regimens for mental and physical disorders. Psychiatr Serv 49, 196-201 (1998).
15. Crawford R., Forrest A.: Controlled trial of depot fluphenazine in out-patient schizophrenics. Br J Psychiatry 124, 385-391 (1974).
16. Davis J.M., Matalon L., Watanabe M.D., Blake L., Metalon L.: Depot antipsychotic drugs. Place in therapy. Drugs 47, 741-773 (1994).
17. Dencker S., Axelsson R.: Optimising the use of depot antipsychotics. CNS Drugs 6, 367-381 (1996).
18. Diaz E., Levine H.B., Sullivan M.C., Sernyak M.J., Hawkins K.A., Cramer J.A., Woods S.W.: Use of the Medication Event Monitoring System to estimate medication compliance in patients with schizophrenia. J Psychiatry Neurosci 26, 325-329 (2001).
19. Dolder C.R., Larco J.P., Dunn L.B., Jeste D.V.: Antipsychotic medication adherence: is there a difference between typical and atypical agents? Am J Psychiatry 159, 103-108 (2002).
20. Eikelmann B.: Nach Enquete und PsychPV - Wie steht es um die soziale Integration schizophrener Patienten? Nervenarzt S4, 499 (2008).
21. Eikelmann B., Reker T., Richter D.: Zur sozialen Exklusion psychisch Kranker - Kritische Bilanz und Ausblick der Gemeindepsychiatrie zu Beginn des 21. Jahrhunderts. Fortschr Neurol Psychiat 73, 664-673 (2005).
22. Fazel S., Khosla V., Doll H., Geddes J.: The prevalence of mental disorder among the homeless in Western countries: systematic review and meta-regression analysis. PLoS Medicine 5, 1670-1681 (2008).
23. Fenton W.S., Blyler C.R., Heinssen R.K.: Determinants of medication compliance in schizophrenia: empirical and clinical findings. Schizophr Bull 23, 637-651 (1997).
24. Fichter M.M., Koniarczyk M., Geifenhagen A., Koegel P., Quadflieg N., Wittchen H.U., Wölz J.: Mental illness in a representative sample of homeless men in Munich, Germany. Eur Arch Psychiatry Clin Neurosci 246, 185-196 (1996).
25. Fitzgerald P.B., deCastella A.R., Filia K.M., Filia S.L., Benitez J., Kulkarni J.: Victimization of patients with schizophrenia and related disorders. Austr NZ J Psychiatry 39, 169-174 (2005).
26. Fleischhacker W.W., Eerdekens M., Karcher K., Remington G., Llorca P.-M., Chrzanowski W., Martin St., Gefvert O.: Treatment of schizophrenia with long-acting risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic. J Clin Psychiatry 64, 1250-1257 (2003).
27. Fleischhacker W.W., Cetkovich-Bakmas M., De Hert M., Hennekens C.H., Lambert M., Leucht S., Maj M., McIntyre R.S., Naber D., Newcomer J.W., Olfson M., Ösby U., Sartorius N., Lieberman J.A.: Comorbid somatic illnesses in patients with severe mental disorders: clinical, policy, and research challenges. J Clin Psychiatry 69, 514-519 (2008).
28. Gerlach J.: Oral versus depot administration of neuroleptics in relapse prevention. Acta Psychiatr Scand 382 (Suppl), 28-32 (1994).
29. Ghaemi S.N.: The case for, and against, evidence-based psychiatry. Acta Psychiatr Scand 119, 249-251 (2009).
30. Gilmer T.P., Dolder C.R., Lacro J.P., Folsom D.P., Lindamer L., Garcia P., Jeste D.V.: Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia. Am J Psychiatry 161,692-699 (2004).
31. Glazer W.M.: Depot neuroleptics: cost-effective and underutilised. JAMA 272, 1272 (1994).
32. Glazer W.M.: Who receives long-acting antipsychotic medications? Psychiatr Serv 58, 437 (2007).
33. Glazer W.M., Ereshefsky L.: A pharmacoeconomic model of outpatient antipsychotic therapy in "revolving door" schizophrenic patients. J Clin Psychiatry 57, 337-345 (1996).
34. Glazer W.M., Kane J.M.: Depot neuroleptic therapy. An underutilized treatment option. J Clin Psychiatry 53, 426-433 (1992).
35. Gutwinski St., Müller P., Koller M.: Rehospitalisierungsfreie Intervalle bei schizophrenen Patienten unter oralen Atypika versus herkömmlichen Depotneuroleptika. Psychiat Prax 34, 289-291 (2007).
36. Hale A.S., Wood C.: Comparison of direct treatment costs for schizophrenia using oral or depot neuroleptics: a pharmacoeconomic analysis. Br J Med Econ 10, 37-45 (1996).
37. Harris E.C., Barraclough B.: Excess mortality of mental disorder. Br J Psychiatry 173, 11-53 (1998).
38. Hawton K., Sutton L., Haw C., Sinclair J., Deeks J.: Schizophrenia and suicide: systematic review of risk factors. Br J Psychiatry 187, 9-20 (2005).
39. Hennekens C.H.: Increasing global burden of cardiovascular disease in general populations and patients with schizophrenia. J Clin Psychiatry 68 (Suppl 4), 4-7 (2007).
40. Heres St., Hamann J., Kissling W., Leucht St.: Attitudes of psychiatrists toward antipsychotic depot medication. J Clin Psychiatry 67, 1948-1953 (2006).
41. Heres St., Schmitz F.S., Leucht St., Pajonk F.-G.: The attitude of patients towards antipsychotic depot treatment. Int Clin Psychopharmacol 22, 275-282 (2007).
42. Hiday V.A., Swartz M.S., Swanson J.W., Borum R., Wagner H.R.: Criminal victimization of persons with severe mental illness. Psychiatr Serv 50, 62-68 (1999).
43. Hiroeh U., Appleby L., Mortensen P.B., Dunn G.: Death by homicide, suicide, and other unnatural causes in people with mental illness. Lancet 358, 2110-2112 (2001).
44. Hogarty G.E., Schooler N.R., Ulrich R., Mussare F., Ferro P., Herron E.: Fluphenazine and social therapy in the aftercare of schizophrenic patients. Relapse analyses of a two-year controlled study of fluphenazine decanoate and fluphenazine hydrochloride. Arch Gen Psychiatry 36, 1283-1294 (1979).
45. Jacobi F., Wittchen H.-U., Hölting C., Höfler M., Pfister H., Müller N., Lieb R.: Prevalence, co-morbidity and correlates of mental disorders in the general population: Results from the German General Health Interview and Examination Survey (GHS). Psychol Med 34, 1-15 (2004).
46. Jeste S.D., PattersonT.L., Palmer B.W., Dolder C.R., Goldman S., Jeste D.V.: Cognitive predictors of medication adherence among middle-aged and older outpatients with schizophrenia. Schizophr Res 63, 49-58 (2003).
47. Johnson D.A.: Observations on the use of long-acting depot neuroleptic injections in the maintenance therapy of schizophrenia. J Clin Psychiatry 45, 13-21 (1984).
48. Johnson D.A.: Antipsychotic medication: clinical guidelines for maintenance therapy. J Clin Psychiatry 46, 6-15 (1985).
49. Kamali M., Kelly B.D., Clarke M., Browne S., Gervin M., Kinsella A., Lane A., Larkin C., O'Callaghan E.: A prospective evaluation of adherence to medication in first episode schizophrenia. Eur Psychiatry 21, 29-33 (2006).
50. Kane J.M.: Treatment adherence and long-term outcomes. CNS Spectr 12 (10 Suppl.17), 21-26 (2007).
51. Kane J.M., Aguglia E., Altamura A.C., Ayuso Gutierrez J.L., Brunello N., Fleischhacker W.W., Gaebel W., Gerlach J., Guelfi J.D., Kissling W., Lapierre Y.D., Lindström E., Mendlewicz J., Racagni G., Carulla J.S., Schooler N.R.: Guidelines for depot antipsychotic treatment in schizophrenia. Eur Neuropsychopharmacology 8, 55-66 (1998).
52. Kavanagh S., Opit L., Knapp M., Beecham J.: Schizophrenia: shifting the balance of care. Soc Psychiatry Psychiatr Epidemiol 30, 206-212 (1995).
53. Kissling W.: Duration of neuroleptic maintenance treatment. In: Kissling W.: Guidelines for neuroleptic relapse prevention in schizophrenia. Proceedings of a consensus conference held April 19-20, 1989, in Bruges, Belgium. Springer, Berlin, Heidelberg 1991, pp 94-106.
54. Knapp M., Ilson S., David A.: Depot antipsychotic preparations in schizophrenia: the state of the economic evidence. Int J Psychopharmacology 12, 135-140 (2002).
55. Knapp M., Mangalore R., Simon J.: The global costs of schizophrenia. Schizophr Bull 30, 279-293 (2004).
56. Konnopka A., Klingberg St., Wittorf A., König H.-H.: Die Kosten der Schizophrenie in Deutschland: Ein systematischer Literaturüberblick. Psychiat Prax 36, 211-218 (2009).
57. Lacro J.P., Dunn L.B., Dolder C.R., Leckbrand S.G., Jeste D.V.: Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry 63, 892-909 (2002).
58. Lam Y.W., Velligan D.I., Dicocco M., Ereshefsky L., Maples N.J., Castillo D.A., Archuletta D., Korell S., Miller A.L.: Comparative assessment of antipsychotic adherence by concentration monitoring, pill count and self-report. Schizophr Res 60 (Suppl), 313 (2003).
59. Larach V., Erazo R., Bustos M., Osorio R., Corrales G., Pizarro F., Gallardo R.: Cost-benefit of a depot neuroleptic clinic: 10 years' follow-up of functioning of a clinical-administrative model. Nordic J Psychiatry 49 (Suppl 35), 57-62 (1995).
60. Lauber C., Anthony M., Ajdacic-Gross V., Rössler W.: What about psychiat rists' attitude to mentally ill people? Eur Psychiatry 19, 423-427 (2004).
61. Lauber C., Keller C., Eichenberger A., Rössler W.: Family burden during exacerbation of schizophrenia: quantification and determinants of additional costs. Int J Soc Psychiatry 51, 259-264 (2005).
62. Leucht S., Burkard T., Henderson J., Maj M., Sartorius N.: Physical illness and schizophrenia: a review of the literature. Acta Psychiatr Scand 116, 317-333 (2007).
63. Lieberman J.A., Koreen A.R., Chakos M., Sheitman B., Woerner M., Alvir J.M., Bilder R.: Factors influencing treatment response and outcome of first-episode schizophrenia: implications for understanding the pathophysiology of schizophrenia. J Clin Psychiatry 57 Suppl 9), 5-9 (1996).
64. Lindholm H., Ljungberg L.: Comparison of conventional neuroleptic therapy with depot neuroleptics. An attempt at economic evaluation. Acta Psychiatr Scand 246, 52-56 (1973).
65. Lögdberg B., Nilsson L.-L., Levander M.T., Levander S.: Schizophrenia, neighbourhood and crime. Acta Psychiatr Scand 110, 92-97 (2004).
66. Loranger A.W.: Sex difference in age at onset of schizophrenia. Arch Gen Psychiatry 41, 157-161 (1984).
67. Marcus S.C., Olfson M.: Outpatient antipsychotic treatment and inpatient costs of schizophrenia. Schizophr Bull 34, 173-180 (2008).
68. McGrath J., Saha S., Welham J., El Saadi O., MacCauley C., Chant D.: A systematic review of the incidence of schizophrenia: the distribution of rates and the influence of sex, urbanicity, migrant status and methodology. BMC Medicine 2, 1-22 (2004).
69. Meise U., Kurz M., Fleischhacker W.W.: Antipsychotic maintenance treatment of schizophrenia patients: Is there a consensus? Schizophr Bull 20, 215-225 (1994).
70. Meise U., Wancata J., Hinterhuber H.: Psychiatrische Versorgung in Österreich: Rückblick - Entwicklungen - Ausblick. Neuropsychiatrie 22, 230-242 (2008).
71. Menzin J., Boulanger L., Friedman M., Mackell J., Lloyd J.R.: Treatment adherence associated with conventional and atypical antipsychotics in a large state Medicaid program. Psychiatr Serv 54, 719-723 (2003).
72. Müller P., Nerenz H., Schaefer E.: Rehospitalisierungsrisiko unter atypischen Neuroleptika und typischen Depotneuroleptika - ein Beitrag zur Differentialindikation. Psychiat Prax 29, 388-391 (2002).
73. Nasrallah H.A.: The case for long-acting antipsychotic agents in the post-CATIE era. Acta Psychiatr Scand 115, 260-267 (2007).
74. Newcomer J.W.: Abnormalities of glucose metabolism associated with atypical antipsychotic drugs. J Clin Psychiatry 65 (Suppl 18), 36-46 (2004).
75. Nordt C., Rössler W., Lauber Ch.: Attitudes of mental health professionals toward people with schizophrenia and major depression. Schizophr Bull 32, 709-714 (2006).
76. Ösby U., Correia N., Brandt L., Ekblom A., Sparen P.: Mortality and causes of death in schizophrenia in Stockholm County, Sweden. Schizophr Res 45, 21-28 (2000).
77. Osborn P.J., Levy G., Nazareth I., Petersen I., Islam A., King M.B.: Relative risk of cardiovascular and cancer mortality in people with severe mental illness from the United Kingdom's General Practice Research Database. Arch Gen Psychiatry 64, 242-249 (2007).
78. Pajonk F.G.: Clinical trial design in schizophrenia: implications for clinical decisions. Curr Opin Psychiatry 18, 692-699 (2005).
79. Palmer B.A., Pankratz V.S., Bostwick J.M.: The lifetime risk of suicide in schizophrenia. A reexamination. Arch Gen Psychiatry 62, 247-253 (2005).
80. Patel M.X., Nikolaou V., David A.S.: Psychiatrists' attitudes to maintenance medication for patients with schizophrenia. Psychol Med 33, 83-89 (2003).
81. Pereira S., Pinto R.: A survey of the attitudes of chronic psychiatric patients living in the community toward their medication. Acta Psychiatr Scand 95, 464-468 (1997).
82. Regier D.A., Farmer M.E., Rae D.S., Locke B.Z., Keith S.J., Judd L.L., Goodwin F.K.: Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. JAMA 264, 2511-2518 (1990).
83. Reker T.: Soziale Exklusion bei Patienten einer psychiatrischen Institutsambulanz. Nervenarzt S4, 50 (2008).
84. Rittmannsberger H., Pachinger Th., Keppelmüller P., Wancata J.: Medication adherence among psychotic patients before admission to inpatient treatment. Psychiatr Serv 55, 174-179 (2004).
85. Rothwell P.M.: External validity of randomised controlled trials: "To whom do the results of this trial apply?" Lancet 365, 82-93 (2005).
86. Roy A.: Suicide in chronic schizophrenia. Br J Psychiatry 141, 171-177 (1982).
87. Saha S., Chant D., Welham J., McGrath J.: A systematic review of the prevalence of schizophrenia. PLoS Medicine 2005;2:e141.doi:10.1371/journal.pmed. 0020141
88. Saha S., Chant D., McGrath J.: A systematic review of mortality in schizophrenia. Arch Gen Psychiatry 64, 1123-1131 (2007).
89. Schanda H., Knecht G., Habeler A.: Der Stellenwert der Depotneuroleptika bei der Behandlung gewalttätiger psychisch Kranker. Neuropsychiatrie 11, 28-32 (1997).
90. Schooler N.R.: Relapse and rehospitalisation: comparing oral and depot antipsychotics. J Clin Psychiatry 64 (Suppl), 14-17 (2003).
91. Shi L., Ascher-Svanum H., Zhu B., Faries D., Montgomery W., Marder S.R.: Characteristics and use patterns of patients taking first-generation depot antipsychotics or oral antipsychotics for schizophrenia. Psychiatr Serv 58, 482-488 (2007).
92. Swartz M.S., Swanson J.W., Wagner R.H., Burns B.J., Hiday V.A.: Effects of involuntary outpatient commitment and depot antipsychotics on treatment adherence in persons with severe mental illness. J Nerv Ment Dis 189, 583-592 (2001).
93. Teplin L.A., McClelland G.M., Abram K.M., Weiner D.A.: Crime victimization in adults with severe mental illness. Arch Gen Psychiatry 63, 911-921 (2005).
94. Thieda P., Beard S., Richter A., Kane J.: An economic review of compliance with medication therapy in the treatment of schizophrenia. Psychiatr Serv 54, 508-516 (2003).
95. Tiihonen J., Wahlbeck K., Lönnqvist J., Klaukka T., Ioannidis J.P.A., Volavka J., Haukka J.: Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow-up study. BMJ 333, 224-229 (2006).
96. Valenstein M., Copeland L.A., Owen R., Blow F.C., Visnic S.: Adherence assessments and the use of depot antipsychotics in patients with schizophrenia. J Clin Psychiatry 62, 545-551 (2001).
97. Valenstein M., Blow F.C., Copeland L.A., McCarthy J.F., Zeber J.E., Gillon L., Bingham C.R., Stavenger T.: Poor antipsychotic adherence among patients with schizophrenia: medication and patient factors. Schizophr Bull 30, 255-264 (2004).
98. Valenstein M., Ganoczy D., McCarthy J.F., Kim H.M., Lee T.A., Blow F.C.: Antipsychotic adherence over time among patients receiving treatment for schizophrenia: a retrospective review. J Clin Psychiatry 67, 1542-1550 (2006).
99. Vanelli M., Burstein Ph., Cramer J.: Refill patterns of atypical and conventional antipsychotic medications at a national retain pharmacy chain. Psychiatr Serv 52, 1248-1250 (2001).
100. Volkow N.D.: Substance use disorders in schizophrenia - clinical implications of comorbidity. Schizophr Bull 35, 469-472 (2009).
101. Walburn J., Gray R., Gournay K., Quraishi S., David A.S.: Systematic review of patient and nurse attitutdes to depot antipsychotic medication. Br J Psychiatry 179, 300-307 (2001).
102. Walsh E., Moran P., Scott C., McKenzie K., Burns T., Creed F., Tyrer P., Murray R.M., Fahy T., UK700 Group: Prevalence of violent victimisation in severe mental illness, Br J Psychiatry 183, 233-238 (2003).
103. Wancata J., Sobocki P., Katschnig H.: Die Kosten von " Gehirnerkrankungen" in Österreich im Jahr 2004. Wien Klin Wochenschr 119, 91-98 (2007).
104. Weiden P.J., Olfson M.: Cost of relapse in schizophrenia. Schizophr Bull 21, 419-429 (1995).
105. Weiden P.J., Kozma C., Grogg A., Locklear J.: Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia. Psychiatr Serv 55, 886-891 (2004).
106. West J.C., Wilk J.E., Olfson M., Rae D.S., Marcus S., Narrow W.E., Pincus H.A., Regier D.A.: Patterns and quality of treatment for patients with schizophrenia in routine psychiatric practice. Psychiatr Serv 56, 283-291 (2005).
107. West J.C., Marcus S.C., Wilk J., Countis L.M., Regier D.A., Olfson M.: Use of depot antipsychotic medications for medication nonadherence in schizophrenia. Schizophr Bull 34, 995-1001 (2008).
108. Wilkinson D.G.: The suicide rate in schizophrenia. Br J Psychiatry 140, 138-141 (1982).
109. Wolthaus J., Dingemans P., Schene A., Linszen D., Wiersma D., van den Bosch R., Cahn W., Hijman R.: Caregiver burden in recent-onset schizophrenia and spectrum disorders: the influence of symptoms and personality traits. J Nerv Ment Dis 190, 241-247 (2002).